Technical Trend Shifts to Sideways from Mildly Bearish
The primary catalyst for the upgrade stems from a marked change in Sandu Pharma’s technical grade. The stock’s technical trend has transitioned from mildly bearish to sideways, indicating a stabilisation in price movement after a period of decline. Key technical indicators present a mixed but improving picture. The weekly MACD is bullish, suggesting upward momentum in the near term, while the monthly MACD remains mildly bullish, supporting a cautiously positive medium-term outlook.
Other indicators such as the weekly Bollinger Bands also show bullish signals, although the monthly bands remain mildly bearish, reflecting some volatility. The daily moving averages are mildly bearish, but the weekly KST (Know Sure Thing) indicator is bullish, offsetting the monthly KST’s bearish stance. Dow Theory assessments align with this mixed view, showing mild bullishness weekly but mild bearishness monthly. Overall, these signals justify the technical upgrade, as the stock price has begun to consolidate rather than decline sharply.
On 2 June 2026, Sandu Pharma’s stock closed at ₹44.09, up 4.98% from the previous close of ₹42.00. The intraday range was ₹40.00 to ₹49.00, with a 52-week high of ₹58.28 and a low of ₹30.00. This price action supports the technical narrative of stabilisation and potential recovery.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Valuation Grade Upgraded to Very Attractive
Alongside technical improvements, Sandu Pharmaceuticals’ valuation grade was upgraded from attractive to very attractive. The company’s price-to-earnings (PE) ratio stands at 27.87, which, while not low in absolute terms, is favourable relative to its sector peers, many of whom are classified as very expensive. The price-to-book value is a modest 1.03, indicating the stock trades close to its book value, a positive sign for value investors.
Enterprise value to EBITDA (EV/EBITDA) is 15.02, and EV to EBIT is 19.86, both suggesting reasonable valuation levels given the company’s earnings profile. The PEG ratio of 2.17 reflects moderate growth expectations relative to earnings, while the dividend yield of 1.78% adds some income appeal. Return on capital employed (ROCE) is 5.22%, and return on equity (ROE) is 3.71%, both low but consistent with the company’s subdued growth trajectory.
Compared to peers such as Indiabulls and Aayush Art, which are very expensive with PE ratios of 14.99 and 228.01 respectively, Sandu Pharma’s valuation appears compelling. This relative discount has contributed to the upgrade in valuation grade, signalling potential upside if operational performance improves.
Financial Trend Remains Flat with Weak Long-Term Fundamentals
Despite the positive shifts in technicals and valuation, Sandu Pharmaceuticals’ financial trend remains flat, reflecting ongoing challenges. The company reported its lowest quarterly net sales of ₹14.07 crores in Q4 FY24-25, underscoring stagnant revenue growth. Over the past five years, net sales have grown at a modest annual rate of 3.54%, while operating profit has increased by 7.49% annually, both below industry averages.
Return on equity has averaged a weak 3.73%, signalling limited profitability relative to shareholder capital. The company’s ability to service debt is also concerning, with an average EBIT to interest ratio of just 1.92, indicating tight coverage and potential financial risk. These factors weigh heavily on the fundamental outlook and justify the stock’s Sell rating despite the upgrade from Strong Sell.
Sandu Pharma has consistently underperformed the benchmark BSE500 index over the last three years, generating a negative 16.81% return in the past year compared to the index’s -8.82%. Over three years, the stock’s return was -24.00% versus the benchmark’s positive 18.96%. This persistent underperformance highlights the company’s struggles to deliver shareholder value.
Technical and Valuation Improvements Temper Negative Fundamentals
The upgrade to Sell from Strong Sell reflects a nuanced view that, while fundamental weaknesses persist, the stock’s technical stabilisation and attractive valuation provide a foundation for potential recovery. The sideways technical trend and bullish weekly indicators suggest the stock may have found a base near current levels. Meanwhile, the valuation discount relative to peers offers a margin of safety for investors willing to tolerate fundamental risks.
Year-to-date, Sandu Pharma has delivered a 17.79% return, outperforming the Sensex’s -12.85% over the same period. This recent relative strength contrasts with longer-term underperformance and may indicate improving investor sentiment. However, caution remains warranted given the company’s flat financial results and weak profitability metrics.
Holding Sandu Pharmaceuticals Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Ownership and Market Capitalisation Context
Sandu Pharmaceuticals is classified as a micro-cap stock, reflecting its relatively small market capitalisation within the pharmaceuticals and biotechnology sector. The majority of its shares are held by non-institutional investors, which can contribute to higher volatility and less predictable trading patterns. This ownership structure may also limit access to institutional support during periods of market stress.
Given the company’s current valuation and technical profile, investors should weigh the risks of limited financial strength against the potential for price stabilisation. The stock’s recent price action, including a 10.34% gain in the past week compared to the Sensex’s 2.90% decline, suggests some renewed interest, but the long-term fundamentals remain a concern.
Conclusion: A Cautious Upgrade Reflecting Mixed Signals
The upgrade of Sandu Pharmaceuticals Ltd’s investment rating from Strong Sell to Sell by MarketsMOJO on 1 June 2026 is driven primarily by improved technical indicators and a more attractive valuation profile. While the company’s financial performance remains flat with weak profitability and growth metrics, the stabilisation in technical trends and relative valuation discount provide a basis for a less negative outlook.
Investors should remain cautious given the company’s persistent underperformance against benchmarks and limited ability to service debt. The Sell rating reflects this balanced view, signalling that while the stock may no longer be a strong sell, it is not yet a buy. Monitoring upcoming quarterly results and sector developments will be critical to reassessing Sandu Pharma’s prospects.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
